Synta Pharmaceuticals Corp.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.syntapharma.com
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 30
- Registration Number
- NCT00827203
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Maryland, United States
🇺🇸University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development, San Antonio, Texas, United States
🇺🇸University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 34
- Registration Number
- NCT00808418
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Maryland, United States
🇺🇸Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, California, United States
🇺🇸University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 53
- Registration Number
- NCT00687934
- Locations
- 🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸US Oncology Dayton Oncology and Hematology, P.A, Kettering, Ohio, United States
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Drug: STA 9090 (ganetespib)
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 45
- Registration Number
- NCT00688116
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center (BIDMC) - Cancer Center, Boston, Massachusetts, United States
A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes
- Conditions
- Active, Moderate to Severe Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 35
- Registration Number
- NCT00642629
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 630
- Registration Number
- NCT00522834
- Locations
- 🇺🇸
The Ohio State University., Columbus, Ohio, United States
🇺🇸Cancer Pavilion, Pittsburgh, Pennsylvania, United States
🇺🇸University of California San Diego Moores UCSD Cancer Center, La Jolla, California, United States
A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic Solid Tumors
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 30
- Registration Number
- NCT00276913
- Locations
- 🇺🇸
Steven Limentani, MD, Charlotte, North Carolina, United States
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2008-12-04
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 12
- Registration Number
- NCT00234741
- Locations
- 🇺🇸
Nih/Niaid, Bethesda, Maryland, United States
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2008-12-04
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 282
- Registration Number
- NCT00138840
- Locations
- 🇺🇸
Maryland Digestive Disease Research, Laurel, Maryland, United States
🇺🇸Capital Gastroenterology Consultants, P.A., Silver Spring, Maryland, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas
- Conditions
- Soft Tissue Sarcoma
- First Posted Date
- 2004-07-23
- Last Posted Date
- 2006-06-20
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 80
- Registration Number
- NCT00087997
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Palm Beach Cancer Institute, West Palm Beach, Florida, United States
🇨🇦Mount Sinai Hospital, Toronto, Ontario, Canada